Sunshine Biopharma Inc. (SBFM) News

Sunshine Biopharma Inc. (SBFM): $1.23

0.07 (+6.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SBFM News Items

SBFM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SBFM News Highlights

  • For SBFM, its 30 day story count is now at 2.
  • Over the past 23 days, the trend for SBFM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest SBFM News From Around the Web

Below are the latest news stories about SUNSHINE BIOPHARMA INC that investors may wish to consider to help them evaluate SBFM as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | January 20, 2023

Sunshine Biopharma Announces Share Repurchase Program

MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with

Yahoo | January 19, 2023

Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares

By Jad Malaeb, Benzinga

Yahoo | December 27, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday!

William White on InvestorPlace | December 22, 2022

Sunshine Biopharma’s Annual Letter to Shareholders

MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company. Dear Fellow Sunshine Biopharma Shareholders, On behalf of Sunshine’s Board of Directors, our senior management team, and employees, we are delighted to have you as our shareholder

Yahoo | December 20, 2022

Sunshine Biopharma Inc. (NASDAQ:SBFM) Is 22.5% Above Its 52-Week Low, But How Long Can It Continue?

In last trading session, Sunshine Biopharma Inc. (NASDAQ:SBFM) saw 0.14 million shares changing hands with its beta currently measuring -1.26. Company’s recent per share price level of $0.80 trading at -$0.06 or -7.39% at ring of the bell on the day assigns it a market valuation of $17.15M. That closing price of SBFM’s stock is … Sunshine Biopharma Inc. (NASDAQ:SBFM) Is 22.5% Above Its 52-Week Low, But How Long Can It Continue? Read More »

Marketing Sentinel | November 26, 2022

EQS-News: NASDAQ: SBFM Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project!

EQS-News: Sunshine Biopharma Inc. NASDAQ: SBFM Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 23.11.2022 / 17:20 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980

Wallstreet:Online | November 23, 2022

NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬

Christine Petraglia - TraDigital IR

Yahoo | November 23, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | November 21, 2022

Sunshine Biopharma Collaborates For Its Lead mRNA-Based Cancer Program

Sunshine Biopharma Inc (NASDAQ: SBFM ) has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1. The company''s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma''s in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma previously showed … Full story available on Benzinga.com

Benzinga | November 16, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6661 seconds.